Clinical Trials
3 trialsNCT03804996 2024-04-08
Study of TG-1801 in Subjects With B-Cell Lymphoma
TG Therapeutics, Inc.
Phase 1 Completed
NCT01647971 2022-11-21
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics, Inc.
Phase 1/2 Completed
NCT03778073 2022-08-22
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
TG Therapeutics, Inc.
Phase 1 Terminated